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Abstract
Nonsurgical approaches involving bronchoscopic lung volume reduction (BLVR) have been developed in the last decade. One of 
these, the BLVR coil procedure, is a treatment option for patients with homogeneous and heterogeneous end-stage emphysema 
and a forced expiratory volume in 1 second (FEV1) of 15–45%. This treatment decreases hyperinflation and improves lung func-
tion, the quality of life, and exercise capacity. It is very important to prepare patients for treatment, premedications, anesthesia 
applications, intubation, post-procedure follow-up and treatments. Further, it has been observed that various complications can 
develop during and after the procedure. Generally, the observed and reported complications are chronic obstructive pulmonary 
disease (COPD) exacerbation, chest pain, mild bleeding, pneumonia, pneumothorax, and respiratory failure. Rarely, aspergillus 
cavitation (coil-related aspergilloma), bronchopleural fistula and penetration into the pleural space, bronchiectasis, coil-associated 
inflammatory response and opacities, and hiccups are observed. Common complications are usually mild or moderate, while the 
rare ones can be life-threatening (except hiccup), so early diagnosis and treatment are necessary. However, patients treated 
with BLVR have lower mortality rates than untreated patients with similar morbidity. Based on the findings of this review, we can 
estimate that premedication one day before and just before the procedure may reduce potential complications. Some medical 
centers apply and recommend 30-day macrolide treatment after the procedure. New generation supraglottic devices may be 
preferred to avoid complications due to endotracheal intubation. Moreover, further research is needed to identify risk factors, 
prevent potential complications, and a common consensus is required for routine preventive treatment.
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Introduction
Emphysema is a chronic lung disease that 
causes pulmonary parenchymal damage, hyper-
inflation, loss of elastic recoil, and progressive 
dyspnea [1]. In the last stage of emphysema, there 
is a marked decrease in exercise capacity and the 
quality of life, and a consequent restriction of dai-
ly activities. During this period, long-acting bron-
chodilators (b2-agonist and anti-muscarinic) and 
drugs (phosphodiesterase-4 inhibitors, methylx-
anthines, and mucolytic agents) are administered 
to reduce the severity of symptoms and frequency 
of exacerbations [2]. In addition, smoking cessa-
tion, education and self-management, nutritional 
support, and pulmonary physiotherapy are rec-
ommended from the early stages of the disease [2]. 
However, when respiratory failure develops after 
a few years, long-term oxygen therapy at home 
becomes necessary, and in cases of hypercapnia, 
non-invasive mechanical ventilation is added [3]. 
While medical treatment of emphysema does not 
impact long-term outcomes in clinical practice, 
invasive treatment can be administered to very 
few patients.
Lung transplantation is an option for patients 
with forced expiratory volume in 1 sec (FEV1) < 
15–20%, but it is often not feasible due to a lack 
of organ availability and the need for specially 
experienced hospital personnel and equipment 
[4]. Studies conducted over the last 10 years have 
reported that the removal of nonfunctional lung 
parenchyma by lung volume reduction surgery 
may increase pulmonary function and improve 
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the quality of life in patients [5, 6]. The 2014 Na-
tional Emphysema Therapy Examination Trial 
emphasized the importance of patient selection 
for this treatment owing to the high incidence 
of postoperative complications (pulmonary and 
non-pulmonary) and early mortality [6].
Therefore, nonsurgical approaches involving 
bronchoscopic lung volume reduction (BLVR) 
have been developed in the last decade. One of 
these, the BLVR coil procedure, is a treatment 
option for patients with homogeneous and het-
erogeneous end-stage emphysema and an FEV1 of 
15–45% [7, 8]. This treatment decreases hyperin-
flation and improves lung function, the quality of 
life, and exercise capacity. In a review covering 
the studies conducted in 2012–2018, BLVR coil 
therapy showed an increase in FEV1 values (mean 
+ 130 mL, 12.1%), a decrease in residual volume 
(RV) (mean -420 mL, 16.5%) and a rise in 6-minute 
walking test (mean + 47 m) [7]. However, the Glob-
al Initiative for Chronic Obstructive Lung Disease 
(GOLD) 2020 guidelines limit BLVR interventions 
to patients with advanced emphysema refractory 
to optimized medical treatment [2]. Further, it has 
been observed that various complications can 
develop during and after the procedure [9].
To this end, the main objective of this review 
is to determine the incidence of complications 
associated with BLVR coil treatment, both during 
the procedure and the follow-up period; to an-
alyze the possible risk factors; and to discuss 
potential treatment options.
Material and methods
Four international databases (Google Scholar, 
Web of Science, SCOPUS and PubMed) have been 
crawled using specified keywords to obtain ap-
propriate articles: endoscopic or bronchoscopic, 
lung volume reduction, coil, complication, and 
case reports. The “Related articles” section in 
Google Scholar and PubMed was used to obtain 
related and similar papers. Original articles, case 
reports, and case series were included.
Features of the BLVR coil procedure
Preparation of patients for the procedure
Patient preparation is very important prior to 
BLVR coil treatment (Table 1). Before the proce-
dure, patients must have quit smoking, received 
pulmonary physiotherapy for at least 6 months, 
and be under optimal medical treatment. Pre-pro-
cedure arterial oxygen partial pressure and carbon 
dioxide partial pressure must be > 50 mm Hg and 
< 55 mm Hg, respectively [9, 10]. It is essential to 
evaluate right ventricular function using transtho-
racic echocardiography prior to the BLVR proce-
dure. Systolic pulmonary artery pressure > 50 mm 
Hg is considered a contraindication for BLVR coil 
therapy. The use of anticoagulants should also be 
considered as the BLVR coil procedure is contrain-
dicated for patients on continuous treatment with 
anticoagulants, although there is no clear contra-
indication for those taking acetylsalicylic acid.
Premedication
Chronic obstructive pulmonary disease 
(COPD) exacerbation and pneumonia are the most 
common complications after the BLVR procedure 
[7]. In addition, acute inflammatory response to 
the procedure, and “coil-associated pneumonitis” 
have also been reported. Hence, many clinicians 
start corticosteroid (prednisolone 30 mg) and an-
tibiotic (azithromycin 250 mg) prophylaxis in the 
preoperative period (1 day before) [10]. Corticoste-
roid treatment for 5 days and antibiotic therapy 
for 30 days after the procedure is recommended 
[10]. Despite insufficient supporting evidence 
in the literature, some BLVR treatment centers 
prefer b-lactam or macrolide use for 5–7 days 
postoperatively. In addition, some centers admin-
ister theophylline 200 mg, prednisolone 40 mg, 
levofloxacin 500 mg, and salbutamol/ipratropium 
nebulization 1 hour before BLVR [11].
Indication and protocol
The procedure is performed in patients with 
emphysema diagnosed by computed tomography 
who exhibit hyperinflated pulmonary functions 
[FEV1: 15–45%, total lung capacity (TLC) > 
100%, RV > 200%, and RV/TLC > 58%] [7, 9, 
10]. Patients diagnosed with any other airway 
disease are not treated using this procedure. 
All coil implantations are performed using fi-
Table 1. Preparation of patients
1. Determination of target lobe by HRCT and perfusion scintig-
raphy
2. Ensuring optimum inhaler treatment
3. Pulmonary physiotherapy (at least 6 months)
4. Smoking cessation (at least 4–6 months in advance)
5. Recommend pneumococcal and influenza vaccines
6. Evaluation of sPAP by echocardiography
7. Arterial blood gas analysis
8. Evaluation of the use of anticoagulants
9. Sputum culture
10. Prophylactic treatment: antibiotic, corticosteroid, nebulizer
HRCT — high resolution computed tomography; sPAP — systolic pulmonary 
artery pressure
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beroptic video bronchoscopy and fluoroscopic 
guidance. Ten standard (8–14 intervals) coils are 
implanted for each lung, and the second proce-
dure is performed within 4–8 weeks. Patients 
without any complications are followed up in the 
hospital for an average of 1 day.
Anesthesia and intubation
Bronchoscopic lung volume reduction coil 
treatments are performed worldwide under gener-
al anesthesia. Generally, intubation with a 9-mm 
endotracheal tube and pressure-controlled venti-
lation at an inspiratory:expiratory ratio of 1:4 and 
respiratory frequency 10/min are preferred [10]. 
One study demonstrated I-gel supraglottic de-
vices (SGD) (Intersurgical Ltd, Berkshire, UK) to 
be a safe alternative to endotracheal intubation 
in BLVR coil treatments [11]. I-gel SGD causes 
less bronchospasms, less mucosal/local trauma, 
and fewer hematomas than rigid bronchoscopy 
and endotracheal intubation, and the incidence 
of arytenoid dislocation is very low [12]. The 
size 8.5 of an endotracheal tube has a 57-mm 
cross-sectional area, while the new generation 
SGDs have a cross-sectional area of 127 mm [13]. 
This is very advantageous in that it makes the 
procedure easier and the complications of endo-
tracheal intubation can be avoided.
Complications of endobronchial coil treatment
The complications of BLVR coil treatment 
can be divided into three groups based on when 
they occur: during the procedure, in the treatment 
recovery (TR) period (< 30 days), and within the 
follow-up phase (> 31 days). Complications in 
the TR and follow-up periods are summarized in 
Tables 2 and 3, respectively.
During the procedure
Previous work has documented procedure-re-
lated complications which include mild bleeding 
(13.3%), coil repositioning and lengthening of 
the procedure (10%), and termination of the 
procedure due to deterioration in hemodynamic 
parameters (2.0%) [14]. In the same study, 31.6% 
of patients had to undergo aspiration of bronchial 
secretion and 8.1% of them showed Pseudomonas 
aeruginosa colonization, the significance of which 
is not yet clear. In addition, bronchospasm, head-
ache, hoarseness, paroxysmal atrial fibrillation, 
and phlebitis may develop due to anesthesia after 
BLVR coil treatment [15].
In the treatment recovery 
and follow-up periods
Various complications can be seen during 
the periods following the BLVR procedure. These 
include bleeding, chest pain, COPD exacerbation, 
pneumonia, pneumothorax, and respiratory 
failure. Treatment recommendations for these 
complications are given in Table 4.
Bleeding
The most common complication observed 
during the TR period is mild bleeding or hemopty-
sis. Studies report the observation of this compli-
Table 2. An overview of treatment recovery period (0 to 30 days) complications in principal studies









Slebos et al. [15] 2012 16 0.72 ± 0.16 28.7 ± 7.1 75.0 21.4 14.2 7.1 3.5 0.0
RESET study [16] 2013 23 0.72 ± 0.17 27.1 ± 8.0 0.0 5.0 — 5.0 5.0 0.0
Klooster et al. [17] 2014 10 0.58 22.0 25.0 15.0 30.0 0.0 5.0 0.0
Deslee et al. [18] 2014 60 0.83 ± 0.25 30.1 ± 6.3 53.9 13.0 24.3 9.5 3.4 0.0
Hartman et al. [19] 2014 38 — 27.0 74.0 — — — 5.2 —
Zoumot et al. [20] 2015 45 0.76 ± 0.20 28.3 ± 8.0 0.0 4.8 1.2 1.2 6.0 0.0
REVOLENS [21] 2016 50 0.75 ± 0.25 25.7 ± 7.5 2.0 8.0 2.0 10.0 6.0 2.0
RENEW [22] 2016 158 0.71 ± 0.20 25.7 ± 6.3 — — — — — —
Gülsen et al. [14] 2017 40 0.68 ± 0.22 26.3 ± 9.1 10.0 — 25.0 — — 0.0
Kontogianni [23] 2017 86 0.71 ± 0.21 27.7 ± 7.0 22.0* 18.5* 5.2* 28.1* 6.1* 3.5*
Simon et al. [24] 2018 33 0.46 ± 0.12 15.0 ± 3.0 — — — — — —
*Adverse events within 3 months.  
Data are shown as percentage. Events per procedure [14–18, 20, 21], events per patients [19, 23] 
COPD — chronic obstructive pulmonary disease; exc. — exacerbation; FEV1 — forced expiratory volume in 1 second; n — patients; pnx — pneumothorax
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cation in 0–75% of cases, whereas severe bleeding 
(> 150 mL) has rarely been noticed and appeared 
to resolve spontaneously in most cases [15–22]. 
Kontogianni et al. [23] reported severe bleeding 
in 3.5% of patients at the 1-year follow-up, and 
3/4 of these patients required surgical interven-
tion. In a study of bleeding complications, 65.3% 
of the subjects showing bleeding were in the TR 
period, and complications were more frequent in 
patients receiving acetylsalicylic acid treatment 
[24]. Bleeding improved spontaneously in 98.5% 
of these patients, and persistent hemoptysis ame-
liorated after bronchial arterial embolization in 
1.5% of the subjects [25]. Therefore, while antico-
agulant use is contraindicated for this procedure, 
patients receiving acetylsalicylic acid therapy 
should also be treated with caution.
Chest pain
Chest pain or discomfort is common in the 
TR period and gradually diminishes during the 
Table 3. An overview of follow-up (after > 31 days) complications in principal studies
Author/study Year COPD exc. Pneumonia Chest Pain Hemoptysis Pnx Resp. failure Death
Slebos et al. [15] 2012 50.0 10.7 7.1 0.0 0.0 — 0.0
RESET study [16] 2013  7.0  0.0 — 0.0 0.0 0.0 0.0
Klooster et al. [17] 2014 35.0  0.0 — 0.0 10.0 0.0 0.0
Deslee et al. [18] 2014 60.2 17.2 10.7 5.3 3.2 0.0 0.0















Zoumot et al. [20] 2015  6.0  1.2 1.2 0.0 3.6 — 11.1
REVOLENS [21] 2016 24.0 12.0 2.0 0.0 2.0 2.0 6.0
RENEW [22] 2016 39.3* 20.0*  — 3.9* 10.3* 3.9* 6.5*
Gülsen et al. [14] 2017 41.4 16.9 25.0 10.0 0.0 — 2.4
Kontogianni [23] 2017 12.3  7.9  0.0 3.5 1.7 2.6 —
Simon et al. [24] 2018 46.3**  5.6**  1.8** 77.7** 0.0** 0.0** 0.0**
*Adverse events within 12 months; **Adverse events within 3 months.
Data are shown as percentage. Events per procedure [14–18, 20, 21]. Events per patients [19, 23]. 
COPD — chronic obstructive pulmonary disease; exc. — exacerbation; FEV1 — forced expiratory volume in 1 second; n — patients; pnx — pneumothorax
Table 4. Possible complications and suggestions [10, 11, 15–27, 30–36]
Complication Rates [%] Suggestions
Aspergillus cavity Rare H, voriconazol
Bleeding, 
     Mild
     Severe
0–75.0
1.5–3.5
M, interruption of acetylsalicylic acid treatment,
arterial embolisation or surgical intervention
Bronchopleural fistula Rare H, VATS or thoracoscopic removal of coil
Bronchiectasis Rare Only M, if patient remained asymptomatic
Chest pain 0–25.0 M, if persist removal of suspected coils near the pleura
Coil-associated inflammation and opacities Rare broad-spectrum antibiotics + systemic corticosteroid (0.5 mg/kg)
COPD exacerbation 0–51.0 H, ± systemic corticosteroid
Hiccup Rare M, if persist removal of suspected coils near diaphragma
Pneumonia 0–46.0 H, broad-spectrum antibiotics ± systemic corticosteroid
Pneumothorax 0–10.3 M, or inserting thorax tube
Respiratory failure 0–3.9 H, NIV or intubation
COPD — chronic obstructive pulmonary disease; H — hospitalization; M — monitoring; NIV — non-invasive ventilation
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follow-up. If the chest pain is continuous and 
pleuritic, the coil implanted close to the pleura 
should be considered as the causative factor 
and assessed for removal. However, it can only 
be removed during the procedure and in the TR 
period [14]. A case of coil removal due to ongoing 
chest pain in the tenth month has been reported 
[26]. However, complete reversibility of the coils 
is not possible.
COPD exacerbations
The most common complication observed 
in the follow-up period is COPD exacerbation. 
Slebos et al. reported that COPD exacerbations 
were more frequent in the first month (here de-
fined as “TR period”), and decreased in frequency 
subsequently [15]. Nevertheless, in a 3-year study, 
51.0%, 37%, and 36% of COPD exacerbations 
were reported over the first, second, and third 
year, respectively [19]. It is thought that the 
frequent occurrence of COPD exacerbations in 
patients undergoing BLVR coil treatment is caused 
by local mucosal injury in the subsegmental 
airways, local edema, and the triggered second-
ary bronchoconstriction [15]. In the REVOLENS 
study, 2 g of amoxicillin/clavulanic acid (in 
the case of allergy, 600 mg of clindamycin plus 
5 mg/kg of gentamicin) was recommended imme-
diately before the BLVR procedure [21]. Although 
there is no clear consensus on preoperative prepa-
ration and therapy, we believe that this treatment 
regimen may be improved, and may reduce some 
complications, including exacerbation of COPD.
Pneumonia
The second most common complication in 
BLVR coil treatments is pneumonia or related 
pneumonitis. In the literature, the incidence of 
pneumonia is reported to be 14.8% on average 
(range 0.0–46.0%) [7]. Therefore, the benefits of 
using steroids and antibiotic regimens in cases 
of pneumonia (or pneumonitis) in the TR period 
should also be investigated in further studies.
Pneumothorax
Another potential complication after BLVR 
coil treatments is pneumothorax. It is observed in 
3.4–6.1% of patients during the TR period [15–20, 
23], and in 0.0–11.6% during the follow-up pe-
riod [15–17, 19–24]. Pneumothorax is a serious 
complication that can cause respiratory failure, 
need for surgery, and even death. Patients who 
develop pneumothorax must be hospitalized and 
monitored. Intercostal drainage or a thorax tube 
can be used if necessary [9]. Although there is 
an algorithm for predicting pneumothorax after 
BLVR valve treatment in the literature, there is 
no specific algorithm for pneumothorax after 
endobronchial coil treatment [27].
Respiratory failure
A possible complication of the BLVR proce-
dure, respiratory failure was reported in 0.0–3.9% 
of patients after the TR period [16, 17, 21–24]. In 
contrast, in a meta-analysis conducted in 2015 in-
volving 140 patients, respiratory failure was not 
reported [28]. These disparate results suggest the 
highly variable rates of respiratory failure, high-
lighting the need for further studies to evaluate 
contributing factors. 
Rare and unexpected complications
There are some rare complications of BLVR 
coil treatments that may have serious conse-
quences. These include Aspergillus cavitation 
(coil-related aspergilloma), bronchopleural fistula 
and penetration into the pleural space, bronchi-
ectasis, coil-associated inflammatory response 
and opacities, and hiccups.
Aspergillus cavitation 
(coil-related aspergilloma)
Two case reports on this complication have 
been recently published [29, 30]. First case con-
cerned the patient who underwent bilateral en-
dobronchial coil treatment during the RENEW 
trial and developed a 27-mm cavity in the left 
upper lobe [29]. The patient was treated with 
voriconazole for 3 months and died due to de-
compensated respiratory failure. In the second 
case, the patient underwent endobronchial coil 
treatment for both upper lobes 3 years earlier [30]. 
Fungal cultures obtained during the procedure 
were positive for Aspergillus species, evaluated 
as colonization. Aspergillus fumigatus positivity 
was continued in the fungal cultures of the pa-
tient who continued spirometric improvement 
for the first 2 years. However, in the third year, 
computed tomography was performed because of 
worsening of dyspnea and frequent acute COPD 
exacerbations. Suspicious masses were observed 
in areas covering the distal end of the coils and 
the diagnosis was confirmed as aspergilloma. The 
patient was treated with voriconazole for about 
14 months, and was discontinued due to cutane-
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ous side effects. Aspergillus was not detected in 
ongoing cultures, clinical findings of the patient 
were stabilized and the follow-up continued. 
These two case reports highlight this rare com-
plication, especially in the long term [29, 30]. 
Bronchopleural fistula and penetration 
into pleural space
This serious complication has been reported 
several times [23, 31–33]. This rare complication 
is due to the direct perforation of the bronchial 
wall and emphysematous tissue after coil im-
plantation. It is usually observed in the first few 
days after the procedure. It may cause respiratory 
insufficiency, and in such cases, the coil should 
be removed thoracoscopically [34]. It is unclear 
whether this complication develops due to the 
proximity of the coils to the pleura; therefore, 
thoracic surgeons should be informed about the 
complication. 
Bronchiectasis
Development of localized bronchiectasis 
a few months after endobronchial coil therapy has 
been reported in one case [35]. The cause of this 
complication and underlying mechanism are not 
yet known. The development of bronchiectasis 
may be an inflammatory response to a compo-
nent of the coil or may be caused by tension in 
the subsegmental region, disrupting the blood 
supply to the bronchial artery and causing local 
ischemia [35]. In addition, the implantation of 
multiple coils into the same subsegment could 
have also led to this complication.
Coil-associated opacities 
and inflammatory response
Bronchoscopic lung volume reduction stud-
ies with lung sealant have revealed a new side 
effect of these treatments. This reaction is de-
fined as the post-treatment acute inflammatory 
response [36, 37]. It usually includes chest pain 
or discomfort, cough, dyspnea, fever, negative 
microbiological findings, increased levels of 
inflammation markers (leukocytosis and high 
C-reactive protein levels), and low oxygen sat-
uration. Similar findings have been found in 
cases of BLVR coil treatments. This phenomenon, 
described as coil-associated opacity (CAO), was 
first reported in 2016 in the RENEW trial [22]. 
The consolidations around the coils can mimic 
organized pneumonia and are usually non-infec-
tious. Although the underlying mechanisms are 
not fully understood, it is generally accepted that 
this is a secondary inflammatory reaction due to 
stress and traction force in the lung tissue, airway 
closure, local airway irritation, or local ischemia 
[10, 21, 22]. It is difficult to differentiate from 
bacterial pneumonia, and some patients may not 
have fever and excess sputum. Corticosteroid 
therapy (0.5 mg/kg) is recommended in addition 
to standard pneumonia treatment [10].
Interestingly, in other lung volume reduction 
procedures such as thermal vapor ablation, local 
inflammatory response is an indication of the 
efficacy of treatment [38]. Similarly, in patients 
who developed CAO after endobronchial coil 
treatment, there was a significant decrease in 
the volume of the targeted and treated lobe after 
complete recovery and resolution. These patients 
are thought to be the best responders [10, 39].
A report of two cases by Perch et al. showed 
a 34% improvement in basal FEV1 in the patient 
who responded well to CAO treatment [40]. In 
the second subject, CAO was not included in the 
preliminary diagnoses and the patient died after 
circulatory collapse. Autopsy revealed necrotiz-
ing inflammation and organized pneumonia in the 
tissues around the coil. This demonstrates that 
CAO can lead to life-threatening consequences if 
not diagnosed and treated early. This suggests that 
patients may have an acute inflammatory reaction 
due to BLVR treatment, and inflammation markers 
must be closely monitored. The high values for 
inflammation markers have the potential to mask 
other infections that may develop, causing new 
infections to be missed. The duration for which 
these laboratory values continue to remain high 
and the extent to which they can be treated are 
separate research topics.
In a different report of two patients with se-
vere upper lobe emphysema, the study subjects 
were treated for community-acquired upper lobe 
pneumonia [41]. After pneumonia treatment and 
resolution, the most diseased and hyperinflated 
lung area lost lobar volume and significant im-
provement in respiratory function was reported. 
The natural and interesting outcome of these indi-
viduals who did not undergo BLVR was similar to 
that of patients who developed CAO after BLVR.
Deaths
Mortality was reported in 0.0–3.5% of pa-
tients after the TR period and 0.0–11.1% of the 
subjects during the follow-up [14–24]. In these 
studies, mortality was not thought to be entirely 
dependent on coil procedures, and deaths due to 
non-procedural/non-respiratory causes such as 
hemorrhagic stroke, severe urinary sepsis, esoph-
ageal cancer can also be observed [19]. However, 
Askin Gulsen, BLVR coil treatment complications and management
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the cause of mortality is usually severe pneumo-
nia, COPD exacerbation, respiratory failure and 
sepsis [14, 19–23].
Hiccups
Hiccups are a very rare complication. It is 
likely caused by the proximity of the coils to the 
diaphragm or the uptake of the diaphragm owing 
to the reduction in lower lobe volume. The inci-
dence rate was reported to be 1.6% in one study, 
and spontaneous recovery has been documented 
[14]. In stubborn cases, removal of the coil may 
be considered.
Discussion
Bronchoscopic lung volume reduction coil 
treatments are an option especially for patients 
with severe hyperinflation and emphysema who 
do not respond to medical/supportive treat-
ments. BLVR coil treatments have been shown 
to improve functional and clinical parameters in 
many studies [14, 15, 17, 20–24]. In the RENEW 
study, which included a 1-year follow-up, partial 
improvement in 6-MWT and respiratory functions 
were reported in those who received coil therapy 
compared to usual care, and any complication 
has been reported in 34.8% of those treated with 
coil therapy and 19.1% in usual care [22]. In 
the REVOLENS study, which included a 2-year 
follow-up, FEV1 and dyspnea score (modified 
Medical Research Council) were not statistically 
significant compared to the initial value, while the 
quality of life score (Saint George’s Respiratory 
Questionnaire), 6-minute walk test and residual 
volume values remained statistically significant 
[21]. Twenty-six patients had 45 serious adverse 
events (SAEs) in the first year, while 27 SAEs in 
twenty patients were observed in the second year. 
As a respiratory complication, 1 lung nodule, 
1 lung transplantation, 4 pneumonia and 12 cases 
of COPD exacerbation were reported, while unex-
pected SAEs and pneumothorax did not develop 
[21]. Considering the potential complications, 
great care must be taken in the selection of the pa-
tients for these treatments. In addition, some stud-
ies did not classify complications as a recover pe-
riod (first 30 days) or follow-up (after > 31 days), 
which naturally leads to a lack of exact rates for 
complications (e.g. 0–75% for bleeding).
Various complications have been reported 
during and after BLVR coil treatments (Figure 
1). Patients should be informed about the com-
plications that may develop and their written 
informed consent must be obtained prior to the 
procedure. Despite the observed complications, it 
can be said that this treatment is effective and safe 
considering the medium- to long-term outcomes 
[14–24]. The high COPD exacerbation rate in the 
studies suggests that the use of premedication, 
prophylactic antibiotics, and corticosteroids is 
warranted. Other observed complications have 
not proven to be preventable after premedication. 
In fact, some complications may be related to the 
experience of the endoscopist. In addition, we 
also recommend that patients should carefully 
monitor their current vaccination status (influen-
za and pneumococcal) because a large proportion 
of persons are at the COPD GOLD III or IV stage. 
We hypothesize that the incidence of some com-
plications in vaccinated patients will be lower, 
although this hypothesis requires future testing.
Mortality rates in the follow-up period after 
BLVR coil therapy were reported to average at 
3.9% (range 0.0–11.1%) [14–24]. A 3-year survival 
rate of 84% was found in the longest follow-up 
study of BLVR coil treatment [19]. All patients 
undergoing BLVR are at the COPD GOLD III and 
GOLD IV stages. Hence, these subjects already 
have a natural comorbidity. A 15-year survival 
rate of 7.3% (5.3% for GOLD III patients and 0.0% 
for GOLD IV patients) was found in all COPD 
groups in a recent study [42]. However, GOLD III 
and IV patients were also reported to have a life 
expectancy of 6.1 and 3.1 years, respectively, 
when hospitalized with exacerbation [42]. The 
situation is not different in individuals with 
emphysema. In a study of an emphysema patient 
group with a mean FEV1 of 26.7 ± 7.0%, mortality 
was reported as 12.7 per 100 person-years over 
a mean follow-up of 3.9 years [43]. These results 
suggest that mortality rates with BLVR are likely 
lower than those in untreated patients with sim-
ilar morbidity.
Patients with emphysema and GOLD IV 
COPD are potential or borderline candidates for 
lung transplantation. According to the guidelines 
of the Pulmonary Transplantation Council of the 
International Society for Heart and Lung Trans-
plantation (2014), persons with FEV1 < 15–20% 
are considered candidates for lung transplanta-
tion [44]. However, when this value is < 25%, 
it is suggested that patients are included in the 
transplantation list [44]. In a published case re-
port, bilateral BLVR coil therapy was applied to 
an end-stage emphysema patient enrolled in the 
lung transplantation list [45]. After treatment, the 
patient’s FEV1 increased from 19% to 21, and the 
RV decreased from 289% to 254%. Transplan-
tation was postponed because of improvement 
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in clinical symptoms and pulmonary function, 
and was performed after 3.5 years. In another 
study, BLVR coil treatments were found to be safe 
during the 12-month follow-up among transplant 
candidate patients with FEV1 values below 25% 
[46]. This result is an example of how BLVR coil 
therapy can buy time for people awaiting lung 
transplantation.
Bacterial colonization in the airway is fre-
quently observed in BLVR coil therapy patients 
and represents a significant opportunity for im-
proved outcomes. In one study, colonization by 
Pseudomonas was reported in 8.1% of patients 
who were treated with BLVR coil treatment [14]. 
A separate 2017 study reported the detection of at 
least one potential pathogen in 47% of the BLVR 
coil patients. These pathogens, Haemophilus 
influenzae, Staphylococcus aureus, Streptococ-
cus pneumoniae, and Pseudomonas aeruginosa, 
were detected in 9%, 6%, 6%, and < 5% of cas-
es, respectively [47]. Therefore, it is important 
to perform sputum examination before the first 
procedure. Although there is no definite contrain-
dication in patients with Pseudomonas aeruginosa 
colonization, it should be kept in mind that this 
may be a relative contraindication if the patient 
has frequent exacerbations or uses antibiotics reg-
ularly. In a case report published by Casutt et al., 
a patient who had previous Pseudomonas infec-
tion but had no growth in current sputum culture 
developed severe pneumonia after endobronchial 
coil treatment [48]. In the post-procedure sputum 
culture, Aspergillus fumigatus and Pseudomonas 
aeruginosa colonies were observed. Risk–benefit 
evaluation of BLVR treatments in patients who 
have previously had bacterial infection or colo-
nization is recommended.
Medical devices manufactured from ma-
terials such as nickel-titanium alloy (nitinol) 
generally have an intrinsic antibacterial effect 
and resistance to bacterial formation [49]. How-
ever, Acinetobacter, Alcaligenes, Pseudomonas, 
Comamonas, Stenotrophomonas, and Aspergillus 
families can develop nickel resistance through 
plasmids and may contribute to CAO or pneu-
monia [50]. An example of this are the cases of 
Aspergillus-associated cavitation [29, 30]. It is thus 
clear that this issue requires further research.
Figure 1. Successful bilateral endobronchial coil implantation (A), bilateral upper lobe coil-associated opacities (B), unilateral left upper lobe coil
-associated opacities (C), left upper lobe coil implantation and pneumothorax (D), right upper lobe coil implantation and pneumonia (E), left upper 
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Conclusions
Bronchoscopic lung volume reduction coil 
therapy is a minimally invasive nonsurgical 
procedure with potential complications in both 
the early and late follow-up periods. However, 
patients treated with BLVR have lower mortality 
rates than untreated patients with similar morbid-
ity. Based on the findings of this review, we can 
estimate that premedication one day before and 
just before the procedure may reduce potential 
complications. Some medical centers apply and 
recommend 30-day macrolide treatment after the 
procedure. New generation SGD may be preferred 
to avoid complications due to endotracheal intu-
bation. Moreover, further research is needed to 
identify risk factors, prevent potential complica-
tions, and a common consensus is required for 
routine preventive treatment.
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